Early Detection of Cancers in Low Resource Countries - Full Text View

Purpose

The purpose of this study is to implement a community-based combined program for early detection of breast, cervical, ovarian and endometrial cancer in low-resource countries delivered through a free standing or a mobile Well Woman Clinic. The goals of this program are to downstage cancers and improve mortality rates using low-cost early detection methods. These programs will be implemented in regions where early cancer detection strategies are not in place and cancers present at advanced stages with resultant high mortality. Currently, there are three target project sites: Cambodia (June 2011), India (June 2011), and Brazil (March 2011). Memorandums of Understanding have been secured with local health organizations in each region to establish clinic operations. Each clinic would serve an approximate target population of 100,000 amongst whom about 12,000 eligible women (4-5,000 annually) will be invited to be screened for breast and cervical cancer over a three-year time span.

Condition	Intervention	Phase
Breast Neoplasms Uterine Cervical Neoplasms Ovarian Neoplasms Endometrial Neoplasms	Procedure: Breast Cancer Screening and Diagnosis Procedure: Cervical Cancer Screening and Diagnosis Procedure: Ovarian Cancer Screening and Diagnosis Procedure: Endometrial Cancer Screening and Diagnosis	Phase 0


Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	Efficacy of a Combined Program for Early Detection of Breast and Gynecological Cancers in Low Resource Countries

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer ovarian cancer

MedlinePlus related topics: Breast Cancer Cancer Cervical Cancer Ovarian Cancer Ultrasound

Genetic and Rare Diseases Information Center resources: Ovarian Cancer

U.S. FDA Resources

Further study details as provided by Woman's Cancer Foundation:

Primary Outcome Measures:

The Effectiveness of an Innovative, Low-Cost Screening and Diagnostic Methodology [ Time Frame: Three (3) year interval ] [ Designated as safety issue: No ]
This study will examine the effectiveness of an innovative, low-cost screening and diagnostic methodology used for combined early detection of breast and gynecological cancers in low resource regions where early cancer detection strategies are not in place and cancers currently are diagnosed at advanced stages with resultant high mortality.

Secondary Outcome Measures:

Effectiveness of CBE and Ultrasonography for Breast Cancer Detection [ Time Frame: Three (3) year interval ] [ Designated as safety issue: No ]
This study will examine the effectiveness of Clinical Breast Examination combined with Ultrasonography for breast cancer screening and detection in low resource settings where X-ray mammography proves not feasible in terms of cost, technology, and staff.


Estimated Enrollment:	36000
Study Start Date:	March 2011
Estimated Study Completion Date:	March 2014
Estimated Primary Completion Date:	March 2014 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Cancer Screening and Diagnosis Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.	Procedure: Breast Cancer Screening and Diagnosis Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases. Other Names: FNAB CBE Ultrasound Procedure: Cervical Cancer Screening and Diagnosis Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases. Other Name: HPV DNA Procedure: Ovarian Cancer Screening and Diagnosis Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer. Other Name: Ultrasound Procedure: Endometrial Cancer Screening and Diagnosis Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding. Other Name: Ultrasound

Groups/Cohorts

Assigned Interventions

Cancer Screening and Diagnosis

Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.

Procedure: Breast Cancer Screening and Diagnosis

Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.

Other Names:

FNAB
CBE
Ultrasound

Procedure: Cervical Cancer Screening and Diagnosis

Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.

Other Name: HPV DNA

Procedure: Ovarian Cancer Screening and Diagnosis

Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.

Other Name: Ultrasound

Procedure: Endometrial Cancer Screening and Diagnosis

Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.

Other Name: Ultrasound

Detailed Description:

We will study the use of sonographic screening in addition to Clinical Breast Examination in low resource settings where screening programs are not currently in place and establishing a population based mammographic screening would be expensive, resource intensive, and difficult if not impossible to implement. The effectiveness of the screening and diagnostic methodology used for early detection of breast, cervical, ovarian and endometrial cancers in low resource settings will be studied. The program would involve screening of asymptomatic women for Breast and Cervical cancer and diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer. Women in the age group of 30-59 yrs will be screened once every three years utilizing the following methods: Breast - clinical breast examination [CBE] and Sonography, followed by Fine needle aspiration biopsy (FNAB) of screen positive cases; Cervical - Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases (Single visit, screen and treat approach); Ovarian - Transvaginal sonogram and clinical evaluation; Endometrial - Transvaginal sonographic assessment of the endometrial stripe.

Eligibility


Ages Eligible for Study:	30 Years to 64 Years (Adult)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Brazil has two rural hospitals serving a population of roughly 46,000 people (Nova Andradina) inside Mato Grosso do Sul, which has a population of over 2 million. Cambodia has a population of over 1 million inside the Phnom Penh metropolitan area. India has a population of more than 1.3 million inside the state of Goa. According to the NFHS-2, nearly 30 percent of rural Goan women live 10 or more kilometers away from a primary health center.

Criteria

Inclusion Criteria:

Breast Cancer: women age 35-64
Cervical Cancer: women age 30-59
Ovarian Cancer: symptomatic post menopausal women age 50-64
Endometrial Cancer: symptomatic post menopausal women age 50-64

Exclusion Criteria:

women under the age of 30

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01178736

Locations


Brazil
Hospital de Cancer de Barretos	Not yet recruiting
Sao Paolo, Brazil
Contact: Edmundo Mauad, MD, PhD (17) 3321-6600 ecmauad@hcancerbarretos.com.br
Principal Investigator: Edmundo Mauad, MD, PhD
Cambodia
Sihanouk Hospital Center of Hope, Hope Worldwide Cambodia	Not yet recruiting
Phnom Penh, Cambodia
Contact: Cornelia Haener, MD (855-23) 882-484 corneliahaener@sihosp.org
Contact: Shelly Malhotra shellymalhotra@sihosp.org
Principal Investigator: Cornelia Haener, MD
India
Manipal Healthcare Group	Not yet recruiting
Goa, India
Contact: R.G. Pinto, MD rgwpinto@gmail.com
Principal Investigator: Sharmila Sardesai, MD
Principal Investigator: R. G. Pinto, MD
Principal Investigator: Eugene D'Silva, MD

Sponsors and Collaborators

Woman's Cancer Foundation

Investigators


Principal Investigator:	Weiwei Yang, MD	M.D. Anderson Cancer Center, University of Texas
Principal Investigator:	Diljeet K Singh, MD	Feinberg School of Medicine, Northwestern University
Principal Investigator:	Adhemar Longatto Filho, MD	University of Sao Paolo

More Information

Publications:

Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. 2005 Mar 9;293(10):1245-56. Review.

Kuhl CK. The "coming of age" of nonmammographic screening for breast cancer. JAMA. 2008 May 14;299(18):2203-5. doi: 10.1001/jama.299.18.2203.

Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K; ACRIN 6666 Investigators. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008 May 14;299(18):2151-63. doi: 10.1001/jama.299.18.2151. Erratum in: JAMA. 2010 Apr 21;303(15):1482.

Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002 Oct;225(1):165-75.

Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology. 2001 Dec;221(3):641-9.

Tohno E, Ueno E, Watanabe H. Ultrasound screening of breast cancer. Breast Cancer. 2009;16(1):18-22. doi: 10.1007/s12282-008-0082-8. Epub 2008 Nov 14.

Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516.

Schiffman M, Wacholder S. From India to the world--a better way to prevent cervical cancer. N Engl J Med. 2009 Apr 2;360(14):1453-5. doi: 10.1056/NEJMe0901167.

Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001 Jun 27;285(24):3107-15. Erratum in: JAMA 2001 Sep 5;286(9):1026.

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007 Jan 15;109(2):221-7.

Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004 Jun 9;291(22):2705-12.

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.

van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007 May 1;109(9):1887-96.

Van den Bosch T, Van Schoubroeck D, Domali E, Vergote I, Moerman P, Amant F, Timmerman D. A thin and regular endometrium on ultrasound is very unlikely in patients with endometrial malignancy. Ultrasound Obstet Gynecol. 2007 Jun;29(6):674-9. Review.

Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, Brand R, Grady D. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998 Nov 4;280(17):1510-7.

Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol. 2002 Apr;99(4):663-70.

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. Review.


Responsible Party:	Mahesh Shetty, MD/President, Woman's Cancer Foundation
ClinicalTrials.gov Identifier:	NCT01178736 History of Changes
Other Study ID Numbers:	WCF-2011-BRA-IND-CAM
Study First Received:	August 6, 2010
Last Updated:	August 8, 2010
Health Authority:	Brazil: Ministry of Health Cambodia: Ministry of Health India: Ministry of Health

Keywords provided by Woman's Cancer Foundation:


neoplasms

Additional relevant MeSH terms:


Neoplasms Breast Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Endometrial Neoplasms Neoplasms by Site Breast Diseases Endocrine Gland Neoplasms Genital Neoplasms, Female Urogenital Neoplasms	Uterine Neoplasms Skin Diseases Ovarian Diseases Adnexal Diseases Genital Diseases, Female Endocrine System Diseases Gonadal Disorders Uterine Cervical Diseases Uterine Diseases

ClinicalTrials.gov processed this record on September 30, 2016